Press Releases

Press Releases
Date Title and Summary View
05/08/2017 Completed enrollment in the first of two patient cohorts in the Phase 1/2 acute myeloid leukemia (AML) trial of GMI-1271 Presented preclinical data for GMI-1271 and GMI-1359 in multiple myeloma at AACR Annual Meeting 2017 Company management will host a conference ca...
05/02/2017 Research demonstrates that E-selectin ligand in myeloma confers more aggressive disease and greater resistance to bortezomib (standard of care) GMI-1271 was able to restore sensitivity to bortezomib ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics...
04/20/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the company will provide an update on clinical data from its Phase 1 and 2 studies of GMI-1271 at the 2017 American Society for Clinical Oncology in Chicago. GMI-1271 is an antagonist of E-selectin, for which prior ...
03/13/2017 Two Long-Time Board Members to Step Down After Company's 2017 Annual Meeting ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Scott Koenig, M.D., Ph.D., to its Board of Directors. Dr. Koenig is President and Chie...
03/07/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that the first of two patient cohorts in its Phase 2 acute myeloid leukemia (AML) trial of GMI-1271 has completed enrollment. This cohort is comprised of 25 patients 60 years of age or older with newly diagnosed AML. The study is ...
03/01/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that pre-clinical research demonstrating the potential of two of its drug candidates, GMI-1271 and GMI-1359, against multiple myeloma will be shared via an oral presentation at the American Association for Cancer Research...
03/01/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today reported progress on its clinical development programs and its financial results for the fourth quarter and year ended December 31, 2016. "In 2016, GlycoMimetics made significant progress across its clinical pipeli...
02/28/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Cowen 37th Annual Health Care Conference in Boston, on Tuesday, March 7, 2017, at 10:40 a.m. ET. To access the live webcast ...
12/05/2016 Results to be presented today in poster at 58th American Society of Hematology (ASH) Annual Meeting and Expo ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that results of its Phase 1/2 clinical trial on its lead drug candidate GMI-1271 conti...
11/10/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows: STIFEL 2016 HEALTHCARE CONFERENCEWHEN: NOVEMBER 15, 2016 AT 4:30 PM E...
FirstPrevious
2
... NextLast
Add to Briefcase = add release to Briefcase